UCSF-CAPRA Prostate Cancer Risk Score
ورودیهای بالینی بیمار
حداقل ۰ — حداکثر ۱۰۰۰ • واحد: ng/mL
حداقل ۳۰ — حداکثر ۱۱۰ • واحد: years
حداقل ۰ — حداکثر ۱۰۰ • واحد: %
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low risk0–2
- Intermediate risk3–5
- High risk6–10
The UCSF-CAPRA Prostate Cancer Risk Score calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include psa. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
UCSF Cancer of the Prostate Risk Assessment (CAPRA, Cooperberg 2005): 0-10 point preoperative score predicting prostate cancer recurrence/ progression risk from PSA, Gleason pattern, clinical stage, age, and percent positive biopsy cores. 0-2 low, 3-5 intermediate, 6-10 high risk.
Clinical Indication
The UCSF-CAPRA Prostate Cancer Risk Score is indicated for bedside clinical practice to support UCSF Cancer of the Prostate Risk Assessment (CAPRA, Cooperberg 2005): 0-10 point preoperative score predicting prostate cancer recurrence/ progression risk from PSA, Gleason pattern, clinical stage, age, and percent positive biopsy cores. 0-2 low, 3-5 intermediate, 6-10 high risk.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival.
CAPRA = PSA(≤6:0, 6.1-10:1, 10.1-20:2, 20.1-30:3, >30:4) + Gleason(no 4/5:0, secondary 4/5:1, primary 4/5:3) + stage(T1/T2:0, T3a:1) + age(<50:0, ≥50:1) + pos cores(<34%:0, ≥34%:1)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| psa | float | Yes | PSA at diagnosis(ng/mL) |
| gleason_pattern | string | Yes | Gleason pattern 4 or 5 |
| clinical_stage | string | Yes | Clinical T stage |
| age | integer | Yes | Age in years(years) |
| percent_positive_cores | float | Yes | Percent of biopsy cores positive(%) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–2 | Low risk | Low risk |
| 3–5 | Intermediate risk | Intermediate risk |
| 6–10 | High risk | High risk |
Evidence-Based References (EBM)
- Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005;173(6):1938-1942.
Related calculators
- UCSF-CAPRA Prostate Cancer Risk Score
- Khorana Risk Score for Venous Thromboembolism in Cancer Patients
- Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC)
- Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes
- Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) Score